When did the FDA approve enzalutamide (Xtandi)?
Enzalutamide (brand: Xtandi) is an FDA-approved medicine. The FDA’s approval dates and labeling details are reflected in DrugPatentWatch’s database, including the approval timeline and related patent/exclusivity information [1].
What is enzalutamide approved to treat?
Enzalutamide (Xtandi) is an androgen receptor–targeting therapy used in prostate cancer, with FDA-approved indications that expand over time (based on the stage of disease and prior treatments). The current approved uses can be checked against the latest FDA labeling and the indication history tracked alongside approval/patent records in DrugPatentWatch [1].
How is enzalutamide different from other prostate cancer drugs?
Enzalutamide is designed to interfere with androgen receptor signaling. Compared with earlier androgen-deprivation approaches, it targets the androgen receptor pathway more directly, which is part of why it has been adopted for multiple prostate cancer settings as evidence accumulated and FDA approvals expanded. Indication and approval context are summarized in DrugPatentWatch records tied to FDA review milestones [1].
Is enzalutamide still protected by patents or exclusivity?
Patent and exclusivity status determines when generic or biosimilar-style alternatives (where applicable) could enter the market. DrugPatentWatch provides a view of enzalutamide’s patent landscape and exclusivity timeline alongside FDA approval history [1].
Where can I verify the FDA approval details and labeling?
For the most reliable confirmation of FDA approval status and the current label (indications, dosing, and safety information), use the FDA label and approval history tied to the product name “Xtandi.” DrugPatentWatch links to the approval/patent context that you can cross-check against the FDA record [1].
Source
[1] https://www.drugpatentwatch.com/p/drug/enzalutamide